AbCellera Biologics Inc. (ABCL) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | -289.0% | -194.9% |
| 2024 | 100.0% | -1091.7% | -564.8% |
| 2023 | 100.0% | -623.8% | -385.0% |
| 2022 | 86.3% | 44.6% | 32.7% |
| 2021 | 87.9% | 54.5% | 40.9% |
Download Data
Export ABCL earnings history in CSV or JSON format
Free sign-in required to download data
AbCellera Biologics Inc. (ABCL) Earnings Overview
As of March 1, 2026, AbCellera Biologics Inc. (ABCL) reported trailing twelve-month net income of -$146M, reflecting +0.1% year-over-year growth. The company earned $-0.49 per diluted share over the past four quarters, with a net profit margin of -1.9%.
Looking at the long-term picture, ABCL's historical earnings data spans multiple years. The company achieved its highest annual net income of $159M in fiscal 2022.
AbCellera Biologics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including REGN ($4.50B net income, 0.3% margin), CNTA (-$243M net income), IMNM (-$223M net income, -32.4% margin), ABCL has room to improve margins relative to the peer group. Compare ABCL vs REGN →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$146M | +10.1% | -$217M | $-0.49 | -194.9% | -289.0% |
| 2024 | -$163M | -11.2% | -$315M | $-0.55 | -564.8% | -1091.7% |
| 2023 | -$146M | -192.4% | -$237M | $-0.51 | -385.0% | -623.8% |
| 2022 | $159M | +3.3% | $217M | $0.50 | 32.7% | 44.6% |
| 2021 | $153M | +29.1% | $204M | $0.48 | 40.9% | 54.5% |
| 2020 | $119M | +5478.5% | $156M | $0.45 | 51.0% | 66.9% |
| 2019 | -$2M | -815.5% | -$4M | $-0.01 | -19.0% | -35.5% |
| 2018 | $309,000 | - | $-753,000 | $0.00 | 3.5% | -8.5% |
See ABCL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABCL Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ABCL vs AGIO
See how ABCL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ABCL growing earnings?
ABCL EPS of $-0.49 reflects slowing growth at +0.1%, below the 5-year CAGR of N/A. TTM net income is $-146M. Expansion rate has moderated.
What are ABCL's profit margins?
AbCellera Biologics Inc. net margin is -1.9%, with operating margin at -2.9%. Below-average margins reflect competitive or cost pressures.
How consistent are ABCL's earnings?
ABCL earnings data spans 2018-2025. The current earnings trend is +0.1% YoY. Historical data enables comparison across business cycles.